alogliptin and actoplus met

Phase 3Small molecule

TThe Fourth Affiliated Hospital of Zhejiang University School of Medicine

alogliptin and actoplus met is one of 19 small molecule programs targeting Metabolism. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MetabolismNot yet recruiting

MetabolismPhase 3

Not yet recruiting

Competition

Competitive Landscape

26 competitors in Metabolism

#DrugCompanyPhaseTrials

Ethanol

Roche

Phase 3

1 2

Cymbalta

Jazz Pharmaceuticals

Phase 1

2 3

Bayer Aspirin

Bayer

Phase 1

1 4

Rapamycin

MMaastricht Radiation Oncology

Phase 2

1 5

Tasmar

BBausch Health Americas, Inc.

Phase 1

1 6

Atropen

FFresenius Kabi Taiwan Ltd.

Phase 1

1 7

alogliptin and actoplus met

TThe Fourth Affiliated Hospital of Zhejiang University School of Medicine

Phase 3

1 8

Exendin-(9-39)

EEiger BioPharmaceuticals

Phase 1

3 9

Obicetrapib

NNewAmsterdam Pharma

Phase 1

1 10

Quemliclustat

Arcus Biosciences

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Post-ApprovalNot yet recruiting

Metabolism

NCT07289750

Clinical

Trials by Indication[1]

Metabolism1 trial

The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD

Not yet recruiting·TThe Fourth Affiliated Hospital of Zhejiang University School of Medicine·Phase 4·NCT07289750·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for alogliptin and actoplus met. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — alogliptin and actoplus met compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for alogliptin and actoplus met. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Fourth Affiliated Hospital of Zhejiang University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TThe Fourth Affiliated Hospital of Zhejiang University School of Medicine

alogliptin and actoplus met

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Metabolism1 trial

References

Drug Info

Quick Facts

Related News